Page 153 - Glucose Monitoring Devices

154 CHAPTER 7 Clinical impact of CGM use

[6] Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of
diabetes. American Journal of Public Health 1991;81:1158e62.
[7] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and
Complications (DCCT/EDIC) Research Group et al. Modern-day clinical course of
type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complica-
tions trial/epidemiology of diabetes interventions and complications and Pittsburgh
epidemiology of diabetes complications experience (1983-2005). Archives of Internal
Medicine 2009;169:1307e16.
[8] Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of inten-
sive glucose control in type 2 diabetes. The New England Journal of Medicine 2008;
359:1577e89.
[9] Martin CL, et al. Neuropathy among the diabetes control and complications trial
cohort 8 years after trial completion. Diabetes Care 2006;29:340e4.
[10] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and
Complications Research Group, et al. Retinopathy and nephropathy in patients with
type 1 diabetes four years after a trial of intensive therapy. The New England Journal
of Medicine 2000;342:381e9.
[11] Zhong GC, Ye MX, Cheng JH, Zhao Y, Gong JP. HbA1c and risks of all-cause and
cause-specific death in subjects without known diabetes: a dose-response meta-
analysis of prospective cohort studies. Scientific Reports 2016;6:24071.
[12] McCoy RG, et al. Increased mortality of patients with diabetes reporting severe
hypoglycemia. Diabetes Care 2012;35:1897e901.
[13] Dahlquist G, Kallen B. Mortality in childhood-onset type 1 diabetes: a population-
based study. Diabetes Care 2005;28:2384e7.
[14] Monnier L, et al. Toward defining the threshold between low and high glucose vari-
ability in diabetes. Diabetes Care 2017;40:832e8.
[15] Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and ther-
apeutic implications. The Lancet Diabetes and Endocrinology 2019;7:221e30.
[16] El-Osta A, et al. Transient high glucose causes persistent epigenetic changes and
altered gene expression during subsequent normoglycemia. Journal of Experimental
Medicine 2008;205:2409e17.
[17] Ceriello A, et al. Oscillating glucose is more deleterious to endothelial function and
oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes
2008;57:1349e54.
[18] Picconi F, et al. Retinal neurodegeneration in patients with type 1 diabetes mellitus: the
role of glycemic variability. Acta Diabetologica 2017;54:489e97.
[19] Yang YF, et al. Visit-to-Visit glucose variability predicts the development of end-stage
renal disease in type 2 diabetes: 10-year follow-up of taiwan diabetes study. Medicine
(Baltimore) 2015;94:e1804.
[20] Dorajoo SR, et al. HbA1c variability in type 2 diabetes is associated with the occur-
rence of new-onset albuminuria within three years. Diabetes Research and Clinical
Practice 2017;128:32e9.
[21] Virk SA, et al. Association between HbA1c variability and risk of microvascular com-
plications in adolescents with type 1 diabetes. The Journal of Cinical Endocrinology
and Metabolism 2016;101:3257e63.